Physical aspects of scintigraphy-based dosimetry for nuclear medicine therapy

NuklearMedizin

Volumn 49, Issue 3, 2010, Pages 85-95

  Geworski, L ^a   Schaefer, A ^b   Knoop, B O ^a   Pinkert, J ^c   Plotkin, M ^d   Kirsch, C M ^b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

^c BAYER AG   (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Dosimetry; Nuclear medicine therapy; Scintigraphy

Indexed keywords

IBRITUMOMAB TIUXETAN; INDIUM 111;

ARTICLE; BONE MARROW; CANCER SCINTISCANNING; COMPUTER PROGRAM; DOSIMETRY; DRUG HALF LIFE; POSITRON EMISSION TOMOGRAPHY; RADIOISOTOPE THERAPY; SCINTIGRAPHY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; URINARY EXCRETION; WHOLE BODY IMAGING; WHOLE BODY SCINTISCANNING;

BONE MARROW; HUMANS; POSITRON-EMISSION TOMOGRAPHY; RADIATION DOSAGE; RADIOISOTOPES; RADIOMETRY; RADIOTHERAPY DOSAGE; SOFTWARE; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; WHOLE BODY IMAGING;

EID: 77952864378     PISSN: 00295566     EISSN: None     Source Type: Journal    
DOI: 10.3413/nukmed-0283     Document Type: Article

References (85)

1. Hainsworth JD, Spigel DR, Markus TM et al. Rituximab plus short-duration chemotherapy followed by yttrium-90 Ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: a phase II trial of the Sarah Cannon Oncology Research Consortium. Clin Lymphoma Myeloma 2009; 9: 223-228.
2. De Jong M, Breeman WA, Kwekkeboom DJ et al. Tumor imaging and therapy using radiolabeled somatostatin analogues. Acc Chem Res 2009; 42: 873-880.
3. De Jong M, Valkema R, Jamar F et al. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. Semin Nucl Med 2002; 32: 133-140.
4. Kwekkeboom DJ, Krenning EP, Lebtahi R et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: peptide receptor radionuclide therapy with radiolabeled somatostatin analogs. Neuroendocrinology 2009; 90: 220-226.
5. Van Essen M, Krenning EP, Kam BL et al. Peptide-receptor radionuclide therapy for endocrine tumors. Nat Rev Endocrinol 2009; 5: 382-393.
6. Morschhauser F, Radford J, Van Hoof A et al. Phase III trial of consolidation therapy with yttrium- 90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 2008; 26: 5156-5164.
7. Kwekkeboom DJ, Mueller-Brand J, Paganelli G et al. Overview of results of peptide receptor radio-nuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med 2005; 46 (Suppl 1): 62S-66S.
8. Zoller F, Eisenhut M, Haberkorn U, Mier W. Endo-radiotherapy in cancer treatment - basic concepts and future trends. Eur J Pharmacol 2009; 625: 55-62.
9. Otte A, van de Wiele C, Dierckx RA. Radiolabeled immunotherapy in non-Hodgkin's lymphoma treatment: the next step. Nucl Med Commun 2009; 30: 5-15.
10. 177Lu-DOTA(0),Tyr(3)] octreotide: which peptide is preferable for PRRT? Eur J Nucl Med Mol Imaging 2006; 33: 1346-1351.
11. Verordnung über den Schutz vor Schäden durch ionisierende Strahlen (StrlSchV). Bundesgesetzblatt I. 2001: 1714 (2002, 1459).
12. Richtlinie nach der Verordnung über den Schutz vor Schäden durch ionisierende Strahlen (StrlSchV) vom 22.04.2002 (Richtlinie Strahlenschutz in der Medizin). Rundschreiben des BMU vom 24.6.2002 - RS II 4 - 11432/1. Verordnung über den Schutz vor Schäden durch ionisierende Strahlen (Strahlenschutzverordnung - StrlSchV) vom 20.07.2001 (BGBI. I S. 1714), zuletzt geändert am 18.06.2002 (BGBI. I S. 1869) BMU; 2004.
13. Thierens HM, Monsieurs MA, Bacher K. Patient dosimetry in radionuclide therapy: the whys and the wherefores. Nucl Med Commun 2005; 26: 593-599. (Pubitemid 40910863)
14. Stabin MG. Update: the case for patient-specific dosimetry in radionuclide therapy. Cancer Biother Radiopharm 2008; 23: 273-284. (Pubitemid 351931455)
15. Sgouros G, Frey E, Wahl R et al. Three-dimensional imagingbased radiobiological dosimetry. Semin Nucl Med 2008; 38: 321-334.
16. Howell RW, Wessels BW, Loevinger R et al. The MIRD perspective 1999. Medical Internal Radiation Dose Committee. J Nucl Med 1999; 40: 3S-10S.
17. Loevinger R, Budinger TF, Watson EE. MIRD Primer for Absorbed Dose Calculations Revised. New York, NY: Society of Nuclear Medicine 1991.
18. Snyder WS, Ford MR, Warner GG, Watson SB. "S," absorbed dose per unit cumulated activity for selected radionuclides and organs. MIRD Pamphlet No. 11. New York: The Society of Nuclear Medicine; 1975.
19. Bolch WE, Bouchet LG, Robertson JS et al. MIRD pamphlet No. 17: the dosimetry of nonuniform activity distributions - radionuclide S values at the voxel level. Medical Internal Radiation Dose Committee. J Nucl Med 1999; 40: 11S-36S.
20. Behr TM, Griesinger F, Riggert J et al. High-dose myeloablative radioimmunotherapy of mantle cell non-Hodgkin lymphoma with the iodine-131-labeled chimeric anti-CD20 antibody C2B8 and autologous stem cell support. Cancer 2002; 94: 1363-1372.
21. 90Y-DOTATOC in association with amino acid infusion: a phase I study. Eur J Nucl Med Mol Imaging 2003; 30: 207-216.
22. 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma. Eur J Nucl Med 2000; 27: 766-777.
23. 90Yibritumomab tiuxetan as consolidation of first remission in advanced-stage follicular lymphoma: results from the international phase 3 first-line indolent trial. J Nucl Med 2009; 50: 1837-1843.
24. Stabin MG. Uncertainties in internal dose calculations for radiopharmaceuticals. J Nucl Med 2008; 49: 853-860. (Pubitemid 351717553)
25. Siegel JA, Thomas SR, Stubbs JB et al. MIRD pamphlet no. 16: Techniques for quantitative radio-pharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med 1999; 40: 37S-61S.
26. Geworski L, Knoop BO, Munz DL. Bildgebende Messtechnik in der Nuklearmedizin. München: Zuckschwerdt 2004.
27. Dillman LT. NM-MIRD pamphlet 6: radionuclide decay schemes and nuclear parameters for use in radiation-dose estimation. 2. J Nucl Med 1970; Suppl 4: 7-32.
28. Dillman LT. Radionuclide decay schemes and nuclear parameters for use in radiationdose estimation. J Nucl Med 1969; 10 (Suppl 2): 1-32.
29. International Commission on Radiological Protection. Radiation dose to patients from radiopharmaceuticals. ICRP Publication 53 ed. New York: Pergamon Press 1987.
30. Cristy M, Eckerman K. Specific Absorbed Fractions of Energy at Various Ages from Internal Photon Sources (I-VII). Oak Ridge National Laboratory Report ORNL/TM-8381/V1-7. Springfield, VA; 1987.
31. Stabin MG, Siegel JA. Physical models and dose factors for use in internal dose assessment. Health Phys 2003; 85: 294-310. (Pubitemid 36999340)
32. Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 2005; 46: 1023-1027. (Pubitemid 43733519)
33. Glatting G, Landmann M, Kull T et al. Internal radionuclide therapy: the ULMDOS software for treatment planning. Med Phys 2005; 32: 2399-2405. (Pubitemid 41023200)
34. Stabin MG. MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 1996; 37: 538-546.
35. Herzog H, Tellmann L, Scholten B et al. PET imaging problems with the non-standard positron emitters yttrium-86 and iodine-124. Q J Nucl Med Mol Imaging 2008; 52: 159-165. (Pubitemid 351721936)
36. Kull T, Ruckgaber J, Weller R et al. Quantitative imaging of yttrium-86 PET with the ECAT EXACT HR+ in 2D mode. Cancer Biother Radiopharm 2004; 19: 482-490. (Pubitemid 39281339)
37. 86Y. Nucl Med Commun 2006; 27: 237-245.
38. Laforest R, Liu X. Image quality with non-standard nuclides in PET. Q J Nucl Med Mol Imaging 2008; 52: 151-158.
39. Buchholz HG, Herzog H, Forster GJ et al. PET imaging with yttrium-86: comparison of phantom measurements acquired with different PET scanners before and after applying background subtraction. Eur J Nucl Med Mol Imaging 2003; 30: 716-720.
40. Pentlow KS, Finn RD, Larson SM et al. Quantitative imaging of yttrium-86 with PET. The occurrence and correction of anomalous apparent activity in high density regions. Clin Positron Imaging 2000; 3: 85-90.
41. Beattie BJ, Finn RD, Rowland DJ, Pentlow KS. Quantitative imaging of bromine-76 and yttrium- 86 with PET: a method for the removal of spurious activity introduced by cascade gamma rays. Med Phys 2003; 30: 2410-2423.
42. Walrand S, Jamar F, Mathieu I et al. Quantitation in PET using isotopes emitting prompt single gammas: application to yttrium-86. Eur J Nucl Med Mol Imaging 2003; 30: 354-361.
43. 86Y-DOTA0)- D-Phe1-Tyr3-octreotide (SMT487) - a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion. Eur J Nucl Med Mol Imaging 2003; 30: 510-518.
44. 90Y-labeled somatostatin analogs. J Nucl Med 2005; 46 (Suppl 1): 92S-98S.
45. Freudenberg LS, Jentzen W, Gorges R et al. 124I-PET dosimetry in advanced differentiated thyroid cancer: therapeutic impact. Nuklearmedizin 2007; 46: 121-128. (Pubitemid 47356534)
46. Jentzen W, Weise R, Kupferschlager J et al. Iodine- 124 PET dosimetry in differentiated thyroid cancer: recovery coefficient in 2D and 3D modes for PET(/CT) systems. Eur J Nucl Med Mol Imaging 2008; 35: 611-623.
47. 124I PET and 3-dimensional-internal dosimetry (3D-ID) software. J Nucl Med 2004; 45: 1366-1372.
48. 131I activity to the salivary glands in radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 2010; 37: 884-895
49. 68Ga- DOTANOC: biodistribution and dosimetry in patients affected by neuroendocrine tumors. Eur J Nucl Med Mol Imaging 2008; 35: 72-79.
50. 68Ga-DOTATOC PET/CT examinations. Nuklearmedizin 2009; 48: 201-207.
51. He B, Frey EC. Comparison of conventional, model-based quantitative planar, and quantitative SPECT image processing methods for organ activity estimation using 111In agents. Phys Med Biol 2006; 51: 3967-3981. (Pubitemid 44177401)
52. 90Y-ibritumomab tiuxetan radioimmunotherapy of patients with non-Hodgkin's lymphoma. Cancer Biother Radiopharm 2008; 23: 53-64.
53. Schaefer A, Schweizer B, Georgi JC et al. Voxel-basierte Ermittlung von Organ- und Herddosen vor und unter interner Radionuklid-Therapie: Erste klinische Erfahrungen mit dem Dosimetrie-Programm STRATOS. Nuklearmedizin 2009; 48: A 48.
54. Hudson HM, Larkin RS. Accelerated image reconstruction using ordered subsets of projection data. IEEE Trans Med Imaging 1994; 13: 601-609.
55. 111In- SPECT. Phys Med Biol 2005; 50: 4169-4185.
56. He B, Wahl RL, Du Y, et al. Comparison of residence time estimation methods for radioimmunotherapy dosimetry and treatment planning - Monte Carlo simulation studies. IEEE Trans Med Imaging 2008; 27: 521-530. (Pubitemid 351479144)
57. Flux G, Bardies M, Monsieurs M et al. The impact of PET and SPECT on dosimetry for targeted radio-nuclide therapy. Z Med Phys 2006; 16: 47-59.
58. 177Lu-DOTA-D-Phe (1)-Tyr (3)-octreotate. Eur J Nucl Med Mol Imaging 2009; 37: 212-225.
59. He B, Frey EC, Tsui BM. Comparison and validation of conjugate view planar, model-based quantitative planar, and quantitative SPECT methods for whole organ activity estimation. J Nucl Med 2005; 46: 50P.
60. International Electrotechnical Commission. IEC 61675-61682: Radionuclide imaging devices - Characteristics and test conditions- Part 2: Single photon emission computed tomographs. Geneva: International Electrotechnical Commission 1998.
61. 111In-Dosimetrie verwendeten Kollimatoren. Nuklearmedizin 2007; 46: P53.
62. Ogawa K, Harata Y, Ichihara T et al. A practical method for position-dependent Compton-scatter correction in single photon emission CT. IEEE Trans Med Imaging 1991; 10: 408-412.
63. Wiseman GA, Leigh B, Erwin WD et al. Radiation dosimetry results for Zevalin radioimmunotherapy of rituximab-refractory non-Hodgkin lymphoma. Cancer 2002; 94 (4 Suppl): 1349-1357.
64. Thomas SR, Stabin MG, Chen CT, Samaratunga RC. MIRD Pamphlet No. 14 revised: A dynamic urinary bladder model for radiation dose calculations. Task Group of the MIRD Committee, Society of Nuclear Medicine. J Nucl Med 1999; 40: 102S-123S.
65. Jaszczak RJ, Greer KL, Floyd CE Jr et al. Improved SPECT quantification using compensation for scattered photons. J Nucl Med 1984; 25: 893-900.
66. Berberich R, Brill G, Schmidt EL. Verbesserung des Auflö sungsvermögens der Gammakamera durch gewichtete Subtraktion der Streustrahlung. Nuc- Compact 1984; 15: 5.
67. King MA, Hademenos GJ, Glick SJ. A dual-photo-peak window method for scatter correction. J Nucl Med 1992; 33: 605-612.
68. Koral KF, Swailem FM, Buchbinder S et al. SPECT dual-energy-window Compton correction: scatter multiplier required for quantification. J Nucl Med 1990; 31: 90-98.
69. Larsson SA. Gamma camera emission tomography. Development and properties of a multi-sectional emission computed tomography system. Acta Radiol Suppl 1980; 363: 1-75.
70. Heidenreich R, Zander A, Knoop BO, Geworski L. Grenzen der Anwendbarkeit geometrischer Mittel-wertbildung in der Dosimetrie für die Absorptionskorrektur. Nuklearmedizin 2007; 46: P47.
71. Sorensen JA. Method for quantitative measurements of radioactivity in vivo by wholebody counting. In: Hine GJ, Sorensen JA (eds). Instrumentation in nuclear medicine. Vol 2. New York: Academic Press 1974: 311-348.
72. Jordan K, Knoop B. Meßtechnik in der Emissions- Computertomographie. In: Diethelm L, Heuck F, Olsson O et al. (eds). Handbuch der medizinischen Radiologie. Vol Bd XV/1B. Berlin: Springer 1988: 281-282.
73. Myers MJ, Lavender JP, de Oliveira JB, Maseri A. A simplified method of quantitating organ uptake using a gamma camera. Br J Radiol 1981; 54: 1062-1067.
74. Stabin MG. Fundamentals of Nuclear Medicine Dosimetry. New York: Springer 2008.
75. 188Re-labelled monoclonal anti-CD66 antibodies. A simplified approach based on a single measurement 3 h p.i. Nuklearmedizin 2006; 45: 134-138.
76. International Commission on Radiological Protection. 1990 Recommendations of the International Commission on Radiological Protection. ICRP Publication 60 ed. New York: Pergamon Press 1991.
77. Dale R, Carabe-Fernandez A. The radiobiology of conventional radiotherapy and its application to radionuclide therapy. Cancer Biother Radiopharm 2005; 20: 47-51.
78. Dale R. The application of the linear-quadratic dose-effect equation to fractionated and protracted radiotherapy. Br J Radiol 1985; 58: 515-528.
79. Sgouros G, Stabin M, Erdi Y et al. Red marrow dosimetry for radiolabeled antibodies that bind to marrow, bone, or blood components. Med Phys 2000; 27: 2150-2164.
80. Cristy M. Active bone marrow distribution as a function of age in humans. Phys Med Biol 1981; 26: 389-400.
81. Sgouros G. Bone marrow dosimetry for radio-immunotherapy: theoretical considerations. J Nucl Med 1993; 34:689-694.
82. Siegel JA, Lee RE, Pawlyk DA et al. Sacral scintigraphy for bone marrow dosimetry in radioimmunotherapy. Int J Rad Appl Instrum B 1989; 16: 553-559.
83. Hindorf C, Linden O, Tennvall J et al. Evaluation of methods for red marrow dosimetry based on patients undergoing radioimmunotherapy. Acta Oncol 2005; 44: 579-588.
84. ICRP. Basic anatomical and physiological data for use in radiological protection: reference values. A report of age- and gender-related differences in the anatomical and physiological characteristics of reference individuals. ICRP Publication 89. Ann ICRP 2002; 32: 5-265.
85. Hindorf C, Glatting G, Chiesa C et al. Guidelines for Bone Marrow and Whole Body Dosimetry. Eur J Nucl Med Mol Imaging 2010; in press.